Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Mar;29(3):415-7.
doi: 10.1089/AID.2012.0233. Epub 2012 Nov 28.

Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients

Emiliano Bissio, Gustavo D Lopardo
Multicenter Study

Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients

Emiliano Bissio et al. AIDS Res Hum Retroviruses. 2013 Mar.
No abstract available

PubMed Disclaimer

References

    1. Bentue-Ferrer D. Arvieux C. Tribut O. Ruffault A. Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: A review. Expert Opin Drug Metab Toxicol. 2009;5:1455–1468. - PubMed
    1. Sanne I. Piliero P. Squires K. Thiry A. Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18–29. - PubMed
    1. Squires K. Lazzarin A. Gatell JM. Powderly WG. Pokrovskiy V. Delfraissy JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011–1019. - PubMed
    1. Wood R. Phanuphak P. Cahn P. Pokrovskiy V. Rozenbaum W. Pantaleo G, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36:684–692. - PubMed
    1. Johnson M. Grinsztejn B. Rodriguez C. Coco J. DeJesus E. Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:153–162. - PubMed

MeSH terms

LinkOut - more resources